Acetylsalicylic acid as an anti-platelet agent: what forms should be used, according to evidence-based medicine?
This analytic paper reviews the evidence on effectiveness, benefits and limitations of one of the best-studied antiplatelet agents – acetylsalicylic acid (ASA). The results of clinical trials, together with so called “gastro-toxicity” of ASA, or Aspirin, and a need for long-term anti-platelet therap...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
«SILICEA-POLIGRAF» LLC
2010-04-01
|
| Series: | Кардиоваскулярная терапия и профилактика |
| Subjects: | |
| Online Access: | https://cardiovascular.elpub.ru/jour/article/view/2043 |
| _version_ | 1797882634045489152 |
|---|---|
| author | O. V. Averkov |
| author_facet | O. V. Averkov |
| author_sort | O. V. Averkov |
| collection | DOAJ |
| description | This analytic paper reviews the evidence on effectiveness, benefits and limitations of one of the best-studied antiplatelet agents – acetylsalicylic acid (ASA). The results of clinical trials, together with so called “gastro-toxicity” of ASA, or Aspirin, and a need for long-term anti-platelet therapy, were the basis for development of various Aspirin forms – soluble, with controlled release, enteric-coated, local (cutaneous), buffer, and combined (Aspirin plus antacids). Currently, the minimal gastro-toxicity has been demonstrated for enteric-coated forms. Specifics of bio-availability, laboratory effects, gastro-intestinal tolerability, and safety could not be the main criteria for choosing a medication form. The choice of an ASA form is defined by the evidence on risk reduction by this form. The extensive evidence on Aspirin as an anti-platelet agent has been obtained in clinical trials using standard ASA. For enteric-coated ASA forms, the evidence on end-point reduction, including mortality reduction, is also available. For other “improved” Aspirin forms, such as buffer, soluble and combined, this evidence is lacking; therefore, their choice could be based only on similarity of laboratory effects and expected lower gastro-toxicity. |
| first_indexed | 2024-04-10T03:38:56Z |
| format | Article |
| id | doaj.art-ed5941b3b99d4d5aa3d02987237f76f7 |
| institution | Directory Open Access Journal |
| issn | 1728-8800 2619-0125 |
| language | Russian |
| last_indexed | 2024-04-10T03:38:56Z |
| publishDate | 2010-04-01 |
| publisher | «SILICEA-POLIGRAF» LLC |
| record_format | Article |
| series | Кардиоваскулярная терапия и профилактика |
| spelling | doaj.art-ed5941b3b99d4d5aa3d02987237f76f72023-03-13T07:23:18Zrus«SILICEA-POLIGRAF» LLCКардиоваскулярная терапия и профилактика1728-88002619-01252010-04-019261681755Acetylsalicylic acid as an anti-platelet agent: what forms should be used, according to evidence-based medicine?O. V. Averkov0Российский университет дружбы народов. МоскваThis analytic paper reviews the evidence on effectiveness, benefits and limitations of one of the best-studied antiplatelet agents – acetylsalicylic acid (ASA). The results of clinical trials, together with so called “gastro-toxicity” of ASA, or Aspirin, and a need for long-term anti-platelet therapy, were the basis for development of various Aspirin forms – soluble, with controlled release, enteric-coated, local (cutaneous), buffer, and combined (Aspirin plus antacids). Currently, the minimal gastro-toxicity has been demonstrated for enteric-coated forms. Specifics of bio-availability, laboratory effects, gastro-intestinal tolerability, and safety could not be the main criteria for choosing a medication form. The choice of an ASA form is defined by the evidence on risk reduction by this form. The extensive evidence on Aspirin as an anti-platelet agent has been obtained in clinical trials using standard ASA. For enteric-coated ASA forms, the evidence on end-point reduction, including mortality reduction, is also available. For other “improved” Aspirin forms, such as buffer, soluble and combined, this evidence is lacking; therefore, their choice could be based only on similarity of laboratory effects and expected lower gastro-toxicity.https://cardiovascular.elpub.ru/jour/article/view/2043ацетилсалициловая кислотаантиагрегантывторичная и первичная профилактика |
| spellingShingle | O. V. Averkov Acetylsalicylic acid as an anti-platelet agent: what forms should be used, according to evidence-based medicine? Кардиоваскулярная терапия и профилактика ацетилсалициловая кислота антиагреганты вторичная и первичная профилактика |
| title | Acetylsalicylic acid as an anti-platelet agent: what forms should be used, according to evidence-based medicine? |
| title_full | Acetylsalicylic acid as an anti-platelet agent: what forms should be used, according to evidence-based medicine? |
| title_fullStr | Acetylsalicylic acid as an anti-platelet agent: what forms should be used, according to evidence-based medicine? |
| title_full_unstemmed | Acetylsalicylic acid as an anti-platelet agent: what forms should be used, according to evidence-based medicine? |
| title_short | Acetylsalicylic acid as an anti-platelet agent: what forms should be used, according to evidence-based medicine? |
| title_sort | acetylsalicylic acid as an anti platelet agent what forms should be used according to evidence based medicine |
| topic | ацетилсалициловая кислота антиагреганты вторичная и первичная профилактика |
| url | https://cardiovascular.elpub.ru/jour/article/view/2043 |
| work_keys_str_mv | AT ovaverkov acetylsalicylicacidasanantiplateletagentwhatformsshouldbeusedaccordingtoevidencebasedmedicine |